Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.
Colorectal cancer is one of the most common causes of cancer-related death in humans. Coptisine (COP) is a natural alkaloid from Coptidis Rhizoma with unclear antitumor mechanism. Human colon cancer cells (HCT-116) and xenograft mice were used to systematically explore the anti-tumor activity of COP in this study. The results indicated that COP exhibited remarkably cytotoxic activities against the HCT-116 cells by inducing G1-phase cell cycle arrest and increasing apoptosis, and preferentially inhibited the survival pathway and induced the activation of caspase proteases family of HCT-116 cells. Experimental results on male BALB/c nude mice confirmed that orally administration of COP at high-dose (150 mg/kg) could suppress tumor growth, and may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in vivo. Taken together, the results suggested that COP may be potential as a novel anti-tumor candidate in the HCT-116 cells-related colon cancer, further studies are still needed to suggest COP for the further use.
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Tao
T
Huang
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.|Department of Clinical Laboratory, Hunan University of Medicine, Hunan 418000, China.
Yubo
Y
Xiao
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing Cancer Institute &Hospital &Cancer Center, Chongqing 400030, China.
Lin
L
Yi
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Ling
L
Li
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Meimei
M
Wang
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Cheng
C
Tian
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Hang
H
Ma
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.|Department of Clinical Laboratory, Hunan University of Medicine, Hunan 418000, China.
Kai
K
He
School of Life Sciences, Southwest University, Chongqing 400715, China.
Yue
Y
Wang
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.
Bing
B
Han
School of Life Sciences, Southwest University, Chongqing 400715, China.|Chongqing Engineering Research Center for Pharmaceutical Process and Quality Control, Chongqing 400716, China.
Xiaoli
X
Ye
School of Chinese Traditional Medicine, School of Pharmaceutical Sciences, Southwest University, Chongqing 400716, China.|Chongqing Engineering Research Center for Pharmaceutical Process and Quality Control, Chongqing 400716, China.
Xuegang
X
Li
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000302:isolation & purification / Q000494:pharmacology; D029064:Araceae / Q000737:chemistry*; D001599:Berberine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology*; D004195:Disease Models, Animal; D045325:HCT116 Cells / Q000187:drug effects*; D064593:Heterografts; D006801:Humans; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C034384:coptisine; D001599:Berberine